Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.
OBJECTIVE
To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods.


METHODS
Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was sacrificed to observe the protective effects of BPC 157 on gastric ulcers.


RESULTS
Both intramuscular (im) and intragastric (ig) administration of BPC 157 could apparently reduce the ulcer area and accelerate the healing of induced ulcer in different models and the effect of im administered BPC 157 was better than that of ig. The rats treated with higher dosages (400 ng/kg, 800 ng/kg) of BPC 157 (im and ig) showed significantly less lesion (P<0.01 vs excipient or saline control), the inhibition ratio of ulcer formation varied between 45.7% and 65.6%, from all measurements except 400 ng/kg BPC 157 in pylorus ligation induced model (P<0.05), in which the inhibition rate was 54.2%. When im administered (800 ng/kg BPC 157) in three models, the inhibition ratio of ulcer formation was 65.5%, 65.6% and 59.9%, respectively, which was better than that of famotidine (its inhibition rate was 60.8%, 57.2% and 34.3%, respectively). Continuous application of BPC 157 (in chronic acetate induced gastric ulcer) could accelerate rebuilding of glandular epithelium and formation of granulation tissue (P<0.05 at 200 ng/kg and P<0.01 at 400 ng/kg and 800 ng/kg vs excipient or saline control).


CONCLUSIONS
Both im and ig administered gastric pentadecapeptide BPC 157 can apparently ameliorate acute gastric ulcer in rats and antagonize the protracted effect of acetate challenge on chronic ulcer. The effect of im administration of BPC 157 is better than that of ig, and the effective dosage of the former is lower than that of the latter.
Xue
Xiao-Chang
XC
Biotechnology Centre, Fourth Military Medical University, 169 West Changle Road, Xi'an 710032, Shaanxi Province, China. xue_xiaochang@yahoo.com
Wu
Yong-Jie
YJ
Gao
Ming-Tang
MT
Li
Wen-Guang
WG
Zhao
Ning
N
Wang
Zeng-Lu
ZL
Bao
Chun-Jie
CJ
Yan
Zhen
Z
Zhang
Ying-Qi
YQ
D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D007273:Injections, Intramuscular; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage*; D011506:Proteins / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013270:Stomach; D013276:Stomach Ulcer / Q000473:pathology*
D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157